• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Leveraging Next-Generation Sequencing Data to Refine Immunotherapy Response Prediction in NSCLC: Programmed Death-Ligand 1 Copy Number, Tumor Mutation Burden, and Beyond.

作者信息

Inamura Kentaro

机构信息

Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

出版信息

J Thorac Oncol. 2023 Sep;18(9):e87-e88. doi: 10.1016/j.jtho.2023.05.009.

DOI:10.1016/j.jtho.2023.05.009
PMID:37599050
Abstract
摘要

相似文献

1
Leveraging Next-Generation Sequencing Data to Refine Immunotherapy Response Prediction in NSCLC: Programmed Death-Ligand 1 Copy Number, Tumor Mutation Burden, and Beyond.利用下一代测序数据优化非小细胞肺癌免疫治疗反应预测：程序性死亡配体1拷贝数、肿瘤突变负荷及其他因素
J Thorac Oncol. 2023 Sep;18(9):e87-e88. doi: 10.1016/j.jtho.2023.05.009.
2
Comment on "Leveraging NGS Data to Refine Immunotherapy Response Prediction in NSCLC: PD-L1 Copy Number, Tumor Mutation Burden, and Beyond".
J Thorac Oncol. 2023 Sep;18(9):e88-e90. doi: 10.1016/j.jtho.2023.05.023.
3
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.综合基因组分析、肿瘤突变负担和 PD-L1 表达的整合，以鉴定非小细胞肺癌免疫治疗的新型生物标志物。
Cancer Med. 2021 Apr;10(7):2216-2231. doi: 10.1002/cam4.3649. Epub 2021 Mar 2.
4
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.利用下一代测序癌症基因 panel 评估血液肿瘤突变负担作为非小细胞肺癌患者免疫治疗的潜在生物标志物。
JAMA Oncol. 2019 May 1;5(5):696-702. doi: 10.1001/jamaoncol.2018.7098.
5
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.采用靶向下一代测序技术对非小细胞肺癌患者进行分析，明确了对抗程序性细胞死亡蛋白 1（PD-1）和抗程序性死亡配体 1（PD-L1）阻断治疗的反应的分子决定因素。
J Clin Oncol. 2018 Mar 1;36(7):633-641. doi: 10.1200/JCO.2017.75.3384. Epub 2018 Jan 16.
6
Association between plasma somatic copy number variations and response to immunotherapy in patients with programmed death-ligand 1-negative non-small cell lung cancer.程序性死亡配体 1 阴性非小细胞肺癌患者血浆体体细胞拷贝数变异与免疫治疗反应的关系。
J Int Med Res. 2022 Apr;50(4):3000605221093222. doi: 10.1177/03000605221093222.
7
Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC.程序性死亡配体 1 拷贝数改变可作为晚期 NSCLC 免疫治疗反应的辅助生物标志物。
J Thorac Oncol. 2023 Jul;18(7):896-906. doi: 10.1016/j.jtho.2023.03.024. Epub 2023 Apr 6.
8
Targeted next-generation sequencing for cancer-associated gene mutation and copy number detection in 206 patients with non-small-cell lung cancer.206 例非小细胞肺癌患者中与癌症相关的基因突变和拷贝数检测的靶向下一代测序。
Bioengineered. 2021 Dec;12(1):791-802. doi: 10.1080/21655979.2021.1890382.
9
Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report.TP53 和 KRAS 共突变可作为鳞状非小细胞肺癌免疫检查点阻断的潜在生物标志物：一例报告。
BMC Med Genomics. 2019 Oct 16;12(1):136. doi: 10.1186/s12920-019-0592-6.
10
Leveraging Transcriptomics Data to Refine Immunotherapy Response Prediction in NSCLC: STK11 Deficiency and Beyond.
J Thorac Oncol. 2023 Nov;18(11):e134-e135. doi: 10.1016/j.jtho.2023.08.021.

引用本文的文献

1
Immune-inflammatory markers and clinical characteristics as predictors of the depth of response and prognosis of patients with PD-L1 ≥50% metastatic non-small cell lung cancer receiving first-line immunotherapy.免疫炎症标志物和临床特征作为接受一线免疫治疗的PD-L1≥50%转移性非小细胞肺癌患者反应深度和预后的预测指标。
Thorac Cancer. 2024 Oct;15(28):2029-2037. doi: 10.1111/1759-7714.15406. Epub 2024 Aug 27.